Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Pancuronium bromide [USAN:USP:INN:BAN:JAN]
RN: 15500-66-0
UNII: U9LY9Y75X2
InChIKey: NPIJXCQZLFKBMV-YTGGZNJNSA-L

Note

  • A Bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than CURARE but has less effect on the circulatory system and on histamine release.

Molecular Formulas

  • C35-H60-Br2-N2-O4
  • C35-H60-N2-O4.2Br

Molecular Weight

  • 732.677
 

Classification Codes

  • Cholinergic Agents
  • Cholinergic Antagonists
  • Drug / Therapeutic Agent
  • Human Data
  • Mutation Data
  • Neuromuscular Agents
  • Neuromuscular Blocking Agent
  • Neuromuscular Blocking Agents
  • Neuromuscular Nondepolarizing Agents
  • Neurotransmitter Agents
  • Nicotinic Antagonists
  • Peripheral Nervous System Agents
  • Reproductive Effect

Names and Synonyms

Name of Substance

  • Pancuronium
  • Pancuronium bromide
  • Pancuronium bromide [USAN:USP:INN:BAN:JAN]

MeSH Heading

  • Pancuronium

Synonyms

  • 1,1'-(3,17-Bis(acetyloxy)androstane-2,16-diyl)bis(1-methylpiperidinium) dibromide
  • 1,1'-(3alpha,17beta-Bis(acetyloxy)-5alpha-androstane-2beta,16beta-diyl)bis(1-methylpiperidinium) dibromide
  • 1,1'-(3alpha,17beta-Dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1-methylpiperidinium) dibromide diacetate
  • 2beta,16beta-Dipiperidino-5alpha-androstane-3alpha,17beta-diol diacetate dimethobromide
  • 2beta,16beta-Dipiperidino-5alpha-androstane-3alpha,17beta-dioldiacetatedimethobromide
  • 3-alpha,17-beta-Diacetoxy-2-beta,16-beta-dipiperidino-5-alpha-androstane dimethobromide
  • 3alpha,17beta-Diacetoxy-2beta,16beta-dipiperidino-5alpha-androstane dimethobromide
  • 5alpha-Androstan-3alpha,17beta-diol, 2beta,16beta-dipipecolinio-, dibromide, diacetate
  • Bromure de pancuronium
  • Bromure de pancuronium [INN-French]
  • Bromuro de pancuronio
  • Bromuro de pancuronio [INN-Spanish]
  • EINECS 239-532-5
  • HSDB 3244
  • Mioblock
  • NA 97
  • NSC 293162
  • ORG NA 97
  • Pancuronii bromidum
  • Pancuronii bromidum [INN-Latin]
  • Pancuronium
  • Pancuronium bromide
  • Pancuronium dibromide
  • Pavulon
  • Piperidinium, 1,1'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1-methyl)-, dibromide
  • Piperidinium, 1,1'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1-methyl-, dibromide
  • Piperidinium, 1,1'-(2-beta,16-beta-(3-alpha,17-beta-dihydroxy-5-alpha-androstanylene))bis(1-methyl-, dibromide, diacetate
  • Piperidinium, 1,1'-(3alpha,17beta-dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1-methyl-, dibromide, diacetate
  • UNII-U9LY9Y75X2

Systematic Names

  • Pancuronium bromide
  • Piperidinium, 1,1'-((2beta,3alpha,5alpha,16beta,17beta)-3,17-bis(acetyloxy)androstane-2,16-diyl)bis(1-methyl)-, dibromide
  • Piperidinium, 1,1'-(2-beta,16-beta-(3-alpha,17-beta-dihydroxy-5-alpha-androstanylene))bis(1-methyl-, dibromide, diacetate
  • Piperidinium, 1,1'-(3alpha,17beta-dihydroxy-5alpha-androstan-2beta,16beta-ylene)bis(1-methyl-, dibromide, diacetate (8CI)

Registry Numbers

CAS Registry Number

  • 15500-66-0

FDA UNII

  • U9LY9Y75X2

System Generated Number

  • 0015500660

Molecular Formulas

Molecular Formulas

  • C35-H60-Br2-N2-O4
  • C35-H60-N2-O4.2Br

Molecular Formula Fragments

  • Br
  • C35-H60-N2-O4
  • COMPONENT

Structure Descriptors

InChI

1S/C35H60N2O4.2BrH/c1-24(38)40-32-21-26-13-14-27-28(35(26,4)23-31(32)37(6)19-11-8-12-20-37)15-16-34(3)29(27)22-30(33(34)41-25(2)39)36(5)17-9-7-10-18-36;;/h26-33H,7-23H2,1-6H3;2*1H/q+2;;/p-2/t26-,27+,28-,29-,30-,31-,32-,33-,34-,35-;;/m0../s1

InChIKey

NPIJXCQZLFKBMV-YTGGZNJNSA-L

Smiles

[Br-].[Br-].CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@@H]([C@@H]4OC(=O)C)[N+]5(C)CCCCC5)[C@@]2(C)C[C@@H]1[N+]6(C)CCCCC6

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
chicken LD50 intravenous 63ug/kg (0.063mg/kg) PERIPHERAL NERVE AND SENSATION: SPASTIC PARALYSIS WITH OR WITHOUT SENSORY CHANGE

LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES

PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE)
Oyo Yakuri. Pharmacometrics. Vol. 5, Pg. 715, 1971.
infant LDLo parenteral 100ug/kg (0.1mg/kg) PERIPHERAL NERVE AND SENSATION: SPASTIC PARALYSIS WITH OR WITHOUT SENSORY CHANGE Archives of Disease in Childhood. Vol. 59, Pg. 73, 1984.
infant TDLo unreported 1mg/kg (1mg/kg) BEHAVIORAL: MUSCLE WEAKNESS Pediatrics. Vol. 77, Pg. 848, 1986.
man LDLo intravenous 143ug/kg (0.143mg/kg) LUNGS, THORAX, OR RESPIRATION: CHRONIC PULMONARY EDEMA

BLOOD: HEMORRHAGE
Journal of Analytical Toxicology. Vol. 4, Pg. 275, 1980.
mouse LD50 intracrebral 3500ng/kg (0.0035mg/kg) BEHAVIORAL: TREMOR

BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD
Oyo Yakuri. Pharmacometrics. Vol. 32, Pg. 465, 1986.
mouse LD50 intraperitoneal 120ug/kg (0.12mg/kg)   Oyo Yakuri. Pharmacometrics. Vol. 32, Pg. 465, 1986.
mouse LD50 intraperitoneal 120ug/kg (0.12mg/kg) LUNGS, THORAX, OR RESPIRATION: DYSPNEA

BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)
Oyo Yakuri. Pharmacometrics. Vol. 32, Pg. 465, 1986.
mouse LD50 intravenous 13ug/kg (0.013mg/kg) LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES

PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE)
Oyo Yakuri. Pharmacometrics. Vol. 5, Pg. 715, 1971.
mouse LD50 oral 21200ug/kg (21.2mg/kg) BEHAVIORAL: GENERAL ANESTHETIC

LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION

BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
Sankyo Kenkyusho Nempo. Annual Report of Sankyo Research Laboratories. Vol. 22, Pg. 187, 1970.
mouse LD50 subcutaneous 167ug/kg (0.167mg/kg)   Drugs in Japan Vol. 6, Pg. 353, 1982.
pig LDLo intravenous 67ug/kg (0.067mg/kg) BEHAVIORAL: REGIDITY

LUNGS, THORAX, OR RESPIRATION: CYANOSIS
British Journal of Anesthesia. Vol. 44, Pg. 91, 1972.
rabbit LD50 intravenous 16ug/kg (0.016mg/kg)   Drugs in Japan Vol. 6, Pg. 353, 1982.
rat LD50 intraperitoneal 479ug/kg (0.479mg/kg) SKIN AND APPENDAGES (SKIN): HAIR: OTHER

BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION
Sankyo Kenkyusho Nempo. Annual Report of Sankyo Research Laboratories. Vol. 22, Pg. 187, 1970.
rat LD50 intravenous 153ug/kg (0.153mg/kg)   Drugs in Japan Vol. 6, Pg. 353, 1982.
rat LD50 oral 202mg/kg (202mg/kg) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION

BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

BEHAVIORAL: GENERAL ANESTHETIC
Sankyo Kenkyusho Nempo. Annual Report of Sankyo Research Laboratories. Vol. 22, Pg. 187, 1970.
rat LD50 subcutaneous 436ug/kg (0.436mg/kg) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION

BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)

BEHAVIORAL: GENERAL ANESTHETIC
Sankyo Kenkyusho Nempo. Annual Report of Sankyo Research Laboratories. Vol. 22, Pg. 187, 1970.

Physical Properties

Physical Property Value Units Temp (deg C) Source
Melting Point 215 deg C   EXP
log P (octanol-water) -1.170 (none)   EST
Water Solubility 5.00E+05 mg/L   EXP
Atmospheric OH Rate Constant 1.29E-10 cm3/molecule-sec 25 EST

Physical property data is provided to ChemIDplus by SRC, Inc.